Biofrontera Inc. to Share Third Quarter Financial Results
Biofrontera Inc. (NASDAQ: BFRI), a prominent player in the biopharmaceutical field, is set to release its financial results for the third quarter of 2025. Scheduled for after the markets close on November 12, 2025, this announcement follows a consistent trend of transparency and shareholder engagement that Biofrontera has upheld since its inception.
Conference Call Details
Following the release of its financial results, Biofrontera will host a conference call on November 13, 2025, at 10:00 AM ET. This call will give stakeholders the opportunity to gain valuable insights into the company’s performance, receive updates on current business initiatives, and have their inquiries addressed by management.
How to Participate in the Conference Call
Participants can join the conference call by dialing 1-877-877-1275 for U.S. inquiries or 1-412-858-5202 for international participants. Be ready to engage with the team and ask any pressing questions regarding the results or market outlook.
Webcast Access Information
For those who prefer an online format, the conference will also be available via a live webcast, with accessible links provided ahead of the event. This ensures that not only analysts but also interested stakeholders can follow along with the presentation and key discussions that arise during the call.
About Biofrontera Inc.
Based in the U.S., Biofrontera Inc. focuses on the development and commercialization of innovative dermatological treatments. Its flagship product, Ameluz, which works in conjunction with the RhodoLED lamp series, provides a cutting-edge photodynamic therapy (PDT) solution for actinic keratosis (AK) and other pre-cancerous skin lesions. Biofrontera’s dedication to clinical research aims to expand the application of PDT for non-melanoma skin cancers and severe acne, ensuring a comprehensive approach to skin health.
Ongoing Commitment to Stakeholders
As part of its commitment to fostering an informed shareholder base, Biofrontera continues to enhance transparency through regular updates and thorough communication. The company encourages all interested parties to stay connected through its website, as well as through social media platforms such as LinkedIn and X, where it shares the latest news, clinical trial results, and product developments.
Investor Relations Contact Information
For additional information or inquiries, investors can reach out to Ben Shamsian at Lytham Partners by calling 646-829-9701 or via email at shamsian@lythampartners.com. Biofrontera values the relationship with its investors and is eager to provide support and insight.
Frequently Asked Questions
What are the main financial results being reported?
Biofrontera will report its earnings for the third quarter, detailing revenue and operational insights.
When can stakeholders access the conference call?
The conference call will be held on November 13, 2025, at 10:00 AM ET.
How can I participate in the conference call?
To join the call, dial 1-877-877-1275 for U.S. and 1-412-858-5202 for international calls.
What key information will Biofrontera provide during the call?
Biofrontera will discuss the financial results, business updates, and address shareholder questions.
Where can I find more information about Biofrontera?
Visit Biofrontera’s official website or follow them on social media channels for the latest updates.